-
Shanghai Junshi Biosciences Partners with Zein Biotechnology for PCSK9 mAb Commercialization in China
•
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced a partnership with compatriot firm Zein Biotechnology to collaborate on the commercialization of its PCSK9 monoclonal antibody (mAb), ongericimab (JS002), in mainland China. The financial details of the agreement have not been disclosed. Regulatory Filings and Phase III…
